Combination treatment for chronic HCV hepatitis in lymphangioleiomyomatosis: first case report.
Bartalesi
F
F
Camiciottoli
G
G
Corti
G
G
Maluccio
N M
NM
Biliotti
E
E
Bartoloni
A
A
Taliani
G
G
D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000150:complications* / Q000503:physiopathology; D018192:Lymphangioleiomyomatosis / Q000150:complications* / Q000503:physiopathology; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a